A B S T R A C T
Background. Patients with end-stage renal disease (ESRD) have high morbidity and mortality rates, with cardiovascular diseases and infections being the major causes of death. Mannosebinding lectin (MBL) has been suggested to play a protective role in this regard. The aim of this study was to investigate a possible clinical association of MBL genotypes (MBL2) with outcome among patients on dialysis or with a functioning graft. Methods. A total of 98 patients with ESRD accepted for livingdonor renal transplantation or on the waiting list for transplantation were included and prospectively followed for an average of 9 years (range 7.5-9.9). Medical records were evaluated regarding transplantation status, diabetes mellitus, vascular parameters and infections for all the patients. Cox regression models and logistic regression analysis were used for statistical analyses. The cohort was divided into two groups according to the MBL2 genotype (normal A/A versus variant A/O or O/O). Results. We found no evidence for an association between the MBL2 genotype and all-cause mortality, cardiovascular events or bacterial infections (pneumonia, urinary tract infection, fistula infection or other infections). Conclusion. In this cohort, the MBL2 genotype did not seem to be associated with any long-term clinical effects in ESRD patients on dialysis or with a functioning graft.
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I N T R O D U C T I O N
Patients with end-stage renal disease (ESRD) have high morbidity and mortality rates. The development of arterial stiffness, dialysis-related infections and pre-diabetes/diabetes is often seen among patients on dialysis therapy, whereas frequent complications in transplant patients are post-transplantation diabetes mellitus (PTDM), deterioration of pre-transplant diabetes and infections due to immunosuppressive treatment. The serum protein mannose-binding lectin (MBL) may play a role in all these clinical complications. Thus aortic stiffness as measured by pulse wave velocity increases the mortality risk and it has been suggested that high levels of serum MBL may have a beneficial role in arterial stiffness among uraemic patients [1] . MBL is an important part of the innate immune system because it recognizes and binds to molecular patterns on the surface of a microorganism and activates the complement system via the lectin pathway, leading to sequestration of the microorganism in the absence of antibodies [2, 3] . The serum concentration of MBL varies considerably between healthy individuals due to the presence of common polymorphic variants present within exon 1 as well as variants in the promoter region of the MBL2 gene that influence serum concentration [4] [5] [6] .
Low serum MBL has been associated with increased bacterial infection susceptibility and disturbances in glucose metabolism [7, 8] . The most common bacterial infections after transplantation are pyelonephritis, pneumonia and sepsis [9] , but the association between MBL deficiency and infections among uraemic or transplanted patients is still not fully understood. Cytomegalovirus (CMV) infection is another frequent complication after kidney transplantation and prophylactic doses of valaciclovir are therefore given post-transplant. A possible association between MBL deficiency and CMV infection or disease has been investigated. This is of particular interest for this study, as one of the important risk factors for developing PTDM is being infected with CMV [10] [11] [12] .
Associations between serum MBL concentrations and mortality among uraemic patients have shown divergent results [13, 14] . The aim of this study was to investigate the long-term effect of the MBL2 genotype on the risk for developing cardiovascular diseases, bacterial infections, PTDM and, in particular, overall mortality. Our hypothesis was that a high serum level of MBL (associated with the MBL2 A/A genotype) offers better infection control, less arterial stiffness and better cardiovascular protection in ESRD patients.
M A T E R I A L S A N D M E T H O D S

Patients and study procedure
This follow-up study is based on a prospective observational cohort study including 98 patients with ESRD. The patients were included as part of a national study of PTDM between January 2006 and March 2008 at the Copenhagen University Hospital, Rigshospitalet and Herlev Hospital. By that time, the patients were scheduled either for a living-donor kidney transplantation (n ¼ 48) or were put on the waiting list for deceased-donor transplantation (n ¼ 50). The patients were between 18 and 65 years of age and had no more than one previous kidney transplantation ( Table 1 ). The transplanted patients were examined three times; by inclusion and again after 3 and 12 months, respectively, where the 12-month diagnosis was considered the correct time for diagnosis of post-transplant diabetes during stable immunosuppression [15] and the waiting list patients only at inclusion and at 12 months later [1, 16] .
During a minimum of 6 years of follow-up, 21 patients died ( Figure 1 ). The remaining cohort was contacted and invited to be re-examined regarding DM and cardiovascular status, Four patients were transplanted before 12 months but returned to dialysis before death. Six patients had been on dialysis all the time.
c Three patients were transplanted after 12 months but returned to dialysis. The study population is here divided by the two different transplantation groups: living donor and deceased donor.
including electrocardiography, arterial stiffness and autonomic neuropathy. Thirty-five patients declined to participate due to time (n ¼ 21), work (n ¼ 6) and health-related conditions (n ¼ 8) and 7 patients did not respond to the inquiry, leaving a total of 35 patients to be re-examined. The examinations were performed after a minimum 10-h overnight fast, including coffee, tobacco and exercise. There were no restrictions on medical intake. All 98 patients' medical records were evaluated and the number of infections, cardiovascular events, eventual diabetes treatment or diagnosis, cancer diagnosis and causes of death were noted. Information from the Danish Society of Nephrology (DNSL) supplied the data required.
The study protocol was approved by the Scientific-Ethical Committee of the Capital Region of Denmark (H-15009280) and the Data Protection Agency (RH-2015-144) and informed written consent was obtained from each subject before participation in the new examinations.
Evaluation of diabetes
A 75-g oral glucose tolerance test (OGTT) was performed according to the World Health Organization criteria by the time of inclusion in the study for all patients with the exception of two with known DM [17] . The OGTT was repeated at each control later on. In the present follow-up examinations, 29 patients performed an OGTT; 4 with known DM and 2 declined.
In addition to the results from the OGTT, the medical records for all 98 patients were evaluated in order to find evidence for a diagnosis of DM; otherwise, they were categorized as having no signs of diabetes. The patients were divided into three different groups: (i) diagnosed with DM before renal transplantation, (ii) diagnosed with DM at any time after renal transplantation (PTDM) and (iii) never diagnosed with DM.
Evaluation of the number of infections and cardiovascular events
By the time of inclusion in the study, four cases with acute myocardial infarctions and five cases with stroke had occurred within the total patient population, as shown in Table 2 . Among these, two patients, one from each different MBL2 group, had suffered from both diseases.
The medical records were evaluated in order to find the number of bacterial infections and cardiovascular events since the date of inclusion in the study. The infections were divided by the most common locations and thus separated into following groups: urinary tract infection, pneumonia, fistula infections and 'other'. Only bacterial infections treated with antibiotics and verified by the microbiology clinic were included in the study.
Cerebral vascular events, pulmonary embolism, acute myocardial infarction and deep venous thrombosis were recorded. Only events verified by either scanning (computed tomography or ultrasound) or coronary angiography were included in the study.
Measurement of serum MBL and assessment of MBL2 genotypes
The assessment of MBL2 genotypes has been described before [1] . In this study we pooled MBL2 structural variants associated with low MBL serum concentrations present on different chromosomes into one variant allele, O. The normal allele is named A.
Immunosuppression
Immunosuppression was given according to a standard regimen as previously described in detail [18, 19] . Immunosuppression consisted primarily of the calcineurin inhibitors cyclosporine or tacrolimus in combination with corticosteroids. Mycophenolate mofetil or mycophenolic acid was used by most patients, while azathioprine was used as an alternative drug.
Statistics
Hazard ratios (HRs) for all-cause mortality were calculated using a Cox model with MBL genotype and sex as binary explanatory variables and age (in 10 years intervals) as a quantitative explanatory variable. In a subanalysis, we further included the cumulated time on dialysis (in months) as a time-varying explanatory variable. Patients were followed from inclusion in the study until death or the end of follow-up, i.e. 21 December 2015.
Cardiovascular event-specific HRs were estimated by a cause-specific Cox regression analysis, where patients were followed from inclusion until first cardiovascular event, death or the end of follow-up, whichever came first. The same explanatory variables as in the all-cause mortality model were used.
The arteriovenous fistula infection-specific MBL2 genotype HR was estimated by a cause-specific Cox analysis where patients were censored at the end of follow-up at first transplantation. Patients were followed from inclusion until the first fistula infection, transplantation, death or the end of follow-up.
In the group of patients who were transplanted within 400 days after inclusion, cause-specific HRs for urinary tract infection, pneumonia and other infections were estimated by Cox regression. Patients were followed from the time of the first onstudy transplantation until the event of interest, death or the end of follow-up. In this analysis, the binary MBL2 genotype and age were included as explanatory variables. Odds ratios (ORs) of DM after 12 months for the MBL2 genotype and transplantation status were calculated using multiple logistic regressions. The transplanted patients were examined for DM 3 and 12 months after the transplant. Only the 12-months diagnosis was used in the logistic regression. The analysis included patients who were non-diabetic at baseline.
R E S U L T S
The cohort was divided into two groups according to MBL2 genotypes ( Table 2 ). One group consisted of patients with the normal A/A genotype (n ¼ 46), whereas the other included patients heterozygous for MBL2 variant A/O (n ¼ 46) or homozygous for the structural variant O/O (n ¼ 6).
Cardiovascular events, bacterial infections and mortality rate
Multiple Cox regression models showed no effect of MBL2 genotypes on the rate of occurrence of either cardiovascular events or mortality (Table 3) , nor bacterial infections. Patients were followed from inclusion in the study until the first event (cardiovascular or bacterial infection), death or the end of follow-up, whichever came first. Sex and age at inclusion in the study were used as covariates. The cumulative incidence for cardiovascular events, treating death as a competing risk according to MBL2 group, is shown in Figure 2 . Further tests were made with cumulative time (months) on dialysis as an additional covariate, adjustments for body mass index (BMI) as a quantitative covariate and smoking status at inclusion, but this did not affect the results. Analyses for urinary tract infections, pneumonia and other infections comprise patients transplanted within the first 400 days only (n ¼ 48). There was no difference in estimated survival between the two MBL2 groups (Figure 3) . The most common causes of death were cardiovascular diseases and infections.
DM
Eight patients had DM by the time of inclusion and three patients developed DM during follow-up while on dialysis treatment. In all, 84 patients were transplanted at any time until the end of follow-up and 19% (16/84) of these patients developed PTDM. The patients were either diagnosed by OGTT results after 3 months (n ¼ 8), 12 months (n ¼ 1) or follow-up (n ¼ 1) or by other physicians in the intervals between examination in our department (n ¼ 6) (Figure 4) . Five of the patients with DM and seven of the patients with PTDM were on pharmacologic treatment. One patient with DM and one with PTDM followed diet restrictions. Thirteen patients (five with DM and eight with PTDM) were not treated.
A total of 84 patients, non-diabetic at baseline, were included in the analysis of development of DM after 12 months. The other patients were excluded from the analysis due to a diagnosis of DM by the time of inclusion (n ¼ 8), death within 12 Patients were followed from inclusion in the study until death, cardiovascular event or the end of follow-up. Cum. dialysis, cumulative time on dialysis. months (n ¼ 2) and lack of participation in any diabetes examination after 12 months (n ¼ 4). The odds of developing DM within 12 months were 5.579 [95% confidence interval (CI) 1.304-38.775; P ¼ 0.037] times higher for a transplanted patient compared with a patient on dialysis with the same age and MBL2 genotype. The estimated 12-months DM OR for MBL2 adjusted for age and transplantation did not demonstrate any association.
D I S C U S S I O N
It is well known that uraemic patients are at increased risk of developing certain comorbidities. Recently, conflicting results regarding the importance of MBL among uraemic patients have been published. The aim of this study was to illustrate any longterm associations of MBL2 genotypes with mortality, infections, diabetes and cardiovascular diseases among uraemic patients. A deficiency of functional MBL due to the presence of MBL2 variant alleles has been suggested to play an important role early in life when the adaptive immune system is still immature, exemplified by Koch et al. [20] , who in a population-based prospective cohort study demonstrated a 2.08-fold (95% CI 1.41-3.06) increased relative risk of acute respiratory tract infections in MBL-insufficient children (A/O or O/O) compared with sufficient children (A/A) during the period from 6 to 18 months of age, whereas after this period there was no association found. Analogous in patients with a coexisting immunodeficiency as in patients with common variable immunodeficiency, low MBL levels seem to be an aggravating factor [21] . Taken together with an absent robust antibody response, MBL deficiency may play a role in immune protection [22, 23] or in patients with other comorbidities such as cystic fibrosis [24, 25] .
We found no evidence for an association between MBL2 genotypes and the development of infections, cardiovascular disease or mortality among patients on dialysis or with a functioning kidney graft during an observation period of 9 years. To be able to compare genetic studies with studies addressing MBL concentrations, it is important to keep in mind that the normal genotype A/A dominates the group above the median if dividing the cohort according to the MBL concentration, as previously published [1] . In 2009, Ibernon et al. [8] showed that MBL concentrations <770 ng/mL in pretransplant uraemic patients involve an increased risk of developing bacterial and mycotic infections compared with patients with higher MBL levels. The discrepancies in our study could be due to differences in clinical characteristics, comorbidities, treatment regimens and follow-up time, 7.5-9.9 years versus 21 6 9 months. Manuel et al. [26] demonstrated significantly lower MBL levels in patients with CMV infection compared with patients without CMV infection, whereas Sagedal et al. [27] did not find any association.
It has previously been demonstrated that high levels of MBL are associated with low pulse wave velocity [1, 28] . Therefore, we FIGURE 4: Diabetes diagnoses. Each bar represents the cumulative diabetes diagnoses at the certain time in the study population. Clinical effects of MBL2 among uraemic patients hypothesized that patients with the MBL2 genotype A/A would have less long-term arterial stiffness and hence better cardiovascular protection. However, the hypothesis was not confirmed in our study, as we could not find any association between the MBL2 genotype and the number of cardiovascular events.
During follow-up, 21 patients died. No association was found between mortality and MBL2 genotype since the patients were almost equally distributed in the two MBL2 genotype groups (A/A, n ¼ 9; A/O or O/O, n¼ 12), as demonstrated in Figure 3 . Major causes of death were infections and cardiovascular disease. This is not in line with the findings from Satomura et al. [14] , who previously suggested that serum levels of MBL <5 mg/mL were associated with increased all-cause mortality among ESRD patients in maintenance haemodialysis [adjusted OR 7.632 (95% CI 2.244-25.961)] after a follow-up period of 36 months.
Furthermore, we found that 19% of the kidney transplanted patients developed PTDM. The odds for developing DM within 12 months is increased by a factor 5.6 among transplanted patients compared with uraemic patients on dialysis therapy. This is in line with previous studies presenting PTDM as a frequent complication after transplantation [8, 19, 29] . Previously, Ibernon et al. [8] demonstrated that low levels of MBL (<770 ng/mL) constitute a risk factor for PTDM. However, an OGTT prior to the transplantation was not done, thus they could not know if a significant proportion of patients were diabetic before transplantation. Hornum et al. [19] , in a national study, found a 12-month incidence of PTDM of 14% in kidney transplanted patients compared with 5% in a control group, where the actual 90 pre-transplant/wait-list non-diabetic patients were included, demonstrating a significant clinical complication after transplantation. Hagen et al. [29] , who followed 95 non-diabetic patients, demonstrated that 22% (14/63) of the patients developed PTDM within 6 years of follow-up and 19% (12/63) of them developed early PTDM 10 weeks after transplantation. The influence of MBL on outcome in diseases affecting the kidneys seems to be rather complex since high levels of MBL have been shown to be associated with an increased risk of developing microalbuminuria or macroalbuminuria and an increased risk of death compared with patients with both low MBL and patients with type 2 diabetes [30] .
This study is rather comprehensive since we have followed the whole cohort from inclusion until death or the end of follow-up, which was 9 years on average (range 7.5-9.9).
Regarding the study limitations, it should be mentioned that we only investigated for bacterial infections and not viral or fungal infections, which could be of interest. Due to previous findings showing an increased prevalence of PTDM after 3 months [8, 19, 29] , the design of this study allowed the patients who were transplanted within the first year after inclusion to be examined three times whereas the patients who were in dialysis 12 months after inclusion were only examined twice. Furthermore, we did not look at differences in immunosuppression between the groups in the cohort, which might have had an impact on the outcomes. Also, no data on physical exercise or diets exist. Relatively few patients are re-examined after a median time of 9 years, with an incidence of 1/35 PTDM (3%) in the study, and therefore more patients with PTDM may have been found. However, going through the medical records for the remaining patients not re-examined, an incidence of PTDM of 7% (3/42) from measurements of glucose or haemoglobin A1c was documented.
C O N C L U S I O N
In conclusion, we demonstrate that the MBL2 genotype does not seem to be associated with long-term effects on the development of infections and cardiovascular disease or mortality among patients on dialysis or with a functioning kidney graft. Our results suggest that MBL is not a predictor for morbidity or mortality among patients with ESRD. In accordance with previous publications, the odds for developing diabetes within 12 months were increased by a factor 5.6 after kidney transplantation compared with being on dialysis.
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